<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893255</url>
  </required_header>
  <id_info>
    <org_study_id>ML28443</org_study_id>
    <nct_id>NCT01893255</nct_id>
  </id_info>
  <brief_title>A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab)</brief_title>
  <official_title>A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Who Are Treated With Tocilizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This observational study will evaluate the use and efficacy of RoActemra/Actemra
      (tocilizumab) in monotherapy in routine clinical practice in patients with rheumatoid
      arthritis. Eligible patients initiated on RoActemra/Actemra treatment according to the
      approved label will be followed for 6 months.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients on RoActemra/Actemra at 6 months after treatment initiation</measure>
    <time_frame>Month 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical/demographic patient characteristics at initiation of RoActemra/Actemra treatment</measure>
    <time_frame>approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of dose modifications/interruptions</measure>
    <time_frame>approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Response according to total joint count evaluation by DAS28/EULAR/SDAI/CDAI/ACR</measure>
    <time_frame>approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment of Disease Activity</measure>
    <time_frame>approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes (Patient Global Assessment of disease activity, HAQ-DI, VAS-Fatigue, severity of pain and morning stiffness)</measure>
    <time_frame>approximately 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra in
        monotherapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Moderate to severe rheumatoid arthritis according to the revised (1987) ACR criteria

          -  Patients in whom the treating physician has made the decision to commence
             RoActemra/Actemra treatment in accordance with the local label; this can include
             patients who have received RoActemra/Actemra treatment within 8 weeks prior to the
             enrolment visit

          -  Patients who for any reason do not take methotrexate and the treating physician has
             made a decision to prescribe RoActemra/Actemra as monotherapy

          -  Patients who were previously on a TNF inhibitor as monotherapy, and the treating
             physician has made a decision to prescribe RoActemra/Actemra as monotherapy

          -  Concomitant treatment with corticosteroids (orally and intra-articularly) and/or
             NSAIDs is allowed

        Exclusion Criteria:

          -  Patients who have received RoActemra/Actemra more than 8 weeks prior to the enrolment
             visit

          -  Patients who have previously received RoActemra/Actemra in a clinical trial or for
             compassionate use

          -  Patients receiving concomitant DMARD treatment for rheumatoid arthritis (e.g.
             hydroxychloroquine, sulfasalazine, methotrexate, leflunomide, gold compounds,
             cyclosporine)

          -  Patients who have received treatment with an investigational agent within 4 weeks (or
             5 half-lives of the investigational agent, whichever is longer) before starting
             treatment with RoActemra/Actemra

          -  Patients with a history of autoimmune disease or any joint inflammatory disease other
             than rheumatoid arthritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <removed_countries>
    <country>Morocco</country>
  </removed_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2013</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

